Net clinical trials

Explore recruiting net clinical trials.

Recruiting net studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Net trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

France, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Poland, Austria, Netherlands, Spain, France, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(Synbiose-2 )Synergetic B-cell immunomodulation in SLE – 2 nd study

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Prasugrel Monotherapy Reduced dose in Acute and Chronic Coronary Syndrome Patients after Percutaneous Coronary Intervention

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Short versus long antiplatelet therapy after TAVI

France

Phase II and Phase III (Integrated) EU CTIS Study details

What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?

Netherlands, Belgium, Italy, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Net trials by city

Net in Toronto Net in Vancouver Net in Montreal Net in Calgary Net in Edmonton Net in Ottawa Net in Winnipeg Net in Quebec City Net in Hamilton Net in Kitchener Net in London Net in Halifax Net in New York Net in Los Angeles Net in Chicago Net in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease